Nuvalent (NUVL) Operating Income (2020 - 2026)
Nuvalent (NUVL) reported Operating Income of -$119.4 million for Q1 2026, down 25.94% on a YoY basis from -$161.2 million in Q1 2025, and down 16.8% quarter-over-quarter from -$102.2 million in Q4 2025.
Nuvalent (NUVL) Operating Income (2020 - 2026) Analysis & Trends
Nuvalent has reported Operating Income for 7 years, with the latest figure at -$119.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 25.94% year-over-year to -$119.4 million; the trailing twelve-month figure through Mar 2026 stood at -$438.9 million (down 36.05% YoY), and the FY2025 full-year result was -$414.3 million, down 47.77% from the prior year.
- Operating Income for Q1 2026 stood at -$119.4 million, down from -$102.2 million in the prior quarter.
- The five-year high for Operating Income was -$17.7 million in Q1 2022, with the low at -$119.4 million in Q1 2026.
- Historically, Operating Income has averaged -$61.7 million across 5 years, with a median of -$52.6 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Income sank 187.05% — and 2025, when it fell 18.46%.
- Nuvalent's Operating Income stood at -$29.3 million in 2022, then plunged by 58.49% to -$46.4 million in 2023, then plunged by 85.84% to -$86.3 million in 2024, then fell by 18.46% to -$102.2 million in 2025, then decreased by 16.8% to -$119.4 million in 2026.
- The last three Operating Income figures came in at -$119.4 million (Q1 2026), -$102.2 million (Q4 2025), and -$112.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -65.83 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -119.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.41 Mn |
| Dec 31, 2025 | -102.23 Mn |
| Sep 30, 2025 | -112.70 Mn |
| Jun 30, 2025 | -104.57 Mn |
| Mar 31, 2025 | -94.81 Mn |
| Dec 31, 2024 | -86.30 Mn |
| Sep 30, 2024 | -76.33 Mn |
| Jun 30, 2024 | -65.15 Mn |
| Mar 31, 2024 | -52.59 Mn |
| Dec 31, 2023 | -46.44 Mn |
| Sep 30, 2023 | -38.78 Mn |
| Jun 30, 2023 | -34.06 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -29.30 Mn |
| Sep 30, 2022 | -20.39 Mn |
| Jun 30, 2022 | -18.73 Mn |
| Mar 31, 2022 | -17.69 Mn |
| Dec 31, 2021 | -17.38 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |